Bioanalysis Zone

Validation of a novel insulin lispro ELISA



Insulin lispro is a rapid-acting insulin analog that was first introduced in 1996 to treat people with diabetes. For an LBA (ligand binding assay) to qualify as a PK assay, several requirements for assay design, as well as analytical performance, are specified in industry guidelines. For insulin lispro, an easy-to-use, high quality PK assay that can meet the pharmaceutical industry requirements for multiple phases of drug development is needed. In addition, differentiating lispro not only from other rapid- and long-acting insulin analogs, but also from native insulin, is a need that demands careful method development.

To find out more and download this poster, please click here!

For more information on Mercodia (Uppsala, Sweden), please click here!

Spotlight on LBA


Leave A Comment